These data suggest that the combination of CTLA4-Ig and low dose IL-2 provides a promising approach to slowing progression in ALS; biomarkers of oxidative stress, proinflammatory cytokines, and cytoskeletal constituents may provide a guide to individual clinical outcomes. Here, CTLA4 is linked to amyotrophic lateral sclerosis.